On April 4th the FDA approved Gilead Sciences new non nucleoside reverse transcriptase inhibitor backbone, DESCOVY. Descovy contains 200mg emtricitabine and 25mg tenofovir alafenamide (TAF) . Descovy contains less than one tenth of the dose of tenofovir compared to Truvada, the NRTI backbone that has been used extensively in antiretroviral regimens for the past 12 years. TRUVADA contains 200mg emtricitabine and 300mg tenofovir disoproxil fumarate (TDF).
DESCOVY is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults and adolescent patients 12 years of age and older.
DESCOVY IS NOT INDICATED FOR USE IN PrEP TO REDUCE THE RISK OF SEXUALLY AQUIRED HIV-1 INFECTION IN ADULTS AT HIGH RISK.
The approval of Descovy is supported by 48-week data from two pivotal Phase 3 studies (Studies 104 and 111) in which the F/TAF-based regimen (administered as Genvoya®; elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg, E/C/F/TAF) met its primary objective of non-inferiority compared to a F/TDF-based regimen (administered as Stribild®; elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg, E/C/F/TDF) among treatment naïve adult patients. Tests of certain renal and bone laboratory parameters favored the F/TAF-based regimen over the F/TDF-based regimen.
You can read the entire Gilead Press Release by clicking here. If you want to know more about Descovy ask your pharmacist and your HIV provider.